Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions

Clinica Chimica Acta

Volumn 324, Issue 1-2, 2002, Pages 1-11

  Benn, Peter A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Aneuploidy; Down syndrome; First trimester; Screening, serum tests; Ultrasound

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CHORION VILLUS SAMPLING; CYTOGENETICS; DOWN SYNDROME; FETUS; FETUS DISEASE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GENETIC COUNSELING; HIGH RISK PREGNANCY; HUMAN; MATERNAL SERUM; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, PRENATAL;

EID: 0036775261     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00187-0     Document Type: Review

References (73)

1. Benn PA, Advances in prenatal screening for Down syndrome: I general principles and second trimester testing. Clin Chim Acta. Submitted for publication.
2. Palomaki G.E., Knight G.J., McCarthy J., Haddow J.E., Donhowe J.M. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am. J. Obstet. Gynecol. 176:1997;1046-1051.
3. Chen J., Heffley D., Beazoglou T., Benn P.A. Utilization of amniocentesis by women screening positive for Down syndrome on the second trimester triple test. Community Genet. 3:2000;24-30.
4. Elias S., Simpson J.L., Bombard A. Amniocentesis and fetal blood sampling. Milunsky A. Genetic disorders of the fetus. 4th ed. 1998;53-82 Johns Hopkins Univ. Press, Baltimore, MD.
5. Rhodes G.G., Jackson L.G., Schlesselman S.E.et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. New Engl. J. Med. 320:1989;609-617.
6. Brambati B., Lanzani A., Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. Chapman M., Grudzinskas J.G., Chard T. The embryo: normal and abnormal development and growth. 1991;181-194 Springer-Velag, London.
7. Wald N.J., Kennard A., Hackshaw A., McGuire A. Antenatal screening for Down's syndrome. J Med Screen 4:1997;181-246. http://www.ncchta.org/fullmono/mon201.pdf.
8. Cuckle H.S., van Lith J.M. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat. Diagn. 19:1999;505-512.
9. Stabile I., Grudzinskas J.G., Chard T. Clinical applications of pregnancy protein estimations with particular reference to pregnancy-associated plasma protein A (PAPP-A). Obstet. Gynecol. Surv. 43:1988;73-82.
10. Westergaard J.G., Sinosich M.J., Bugge M., Masen L.T., Teisner B., Grudzinskas J.G. Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am. J. Obstet. Gynecol. 145:1983;67-69.
11. Haddow J., Palomaki G.E., Knight G.J., Williams J., Miller W.A., Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. New Engl. J. Med. 338:1998;955-961.
12. Hallahan T., Krantz D., Orlandi F.et al. First trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG. Prenat. Diagn. 20:2000;785-789.
13. Spencer K., Berry E., Crossley J.A., Aitken D.A., Nicolaides K.H. Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy? Prenat. Diagn. 20:2000;311-317.
14. Wald N.J., Kennard A., Hackshaw A.K. First trimester serum screening for Down syndrome. Prenat. Diagn. 15:1995;1227-1240.
15. Ozturk M., Bellet D., Manil L., Hennen G., Frydman R., Wands J. Physiological studies on human chorionic gonodotropin (hCG), αhCG, and βhCG as measured by specific monoclonal immunoradiometric assays. Endocrinol. 120:1987;549-558.
16. Qin Q.P., Christiansen M., Nguyen T.H., Sorensen S., Larsen S.O., Norgaard-Pedersen B. Schwangerschaftsprotein 1 (SP1) as a maternal serum marker for Down syndrome in the first and second trimesters. Prenat. Diagn. 17:1997;101-108.
17. Christiansen M., Oxvig C., Wagner J.M.et al. The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome. Prenat. Diagn. 19:1999;905-910.
18. Morez C., Maymon R., Jauniaux E., Traub L., Cuckle H. Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component. Prenat. Diagn. 20:2000;395-399.
19. Spencer K., Noble P., Snijders R.J.M., Nicolaides K.H. First trimester free beta hCG, beta core and total estriol in pregnancies affected by Down syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG. Prenat. Diagn. 17:1997;525-538.
20. Cuckle H.S., Canick J.A., Kellner L.H.et al. Urinary β-core hCG screening in the first trimester. Prenat. Diagn. 16:1996;1057-1059.
21. Cuckle H.S., Canick J.A., Kellner L.H. Collaborative study of maternal urine β-core human chorionic gonadotropin screening for Down syndrome. Prenat. Diagn. 19:1999;911-917.
22. Weinans M.J., Butler S.A., Mantingh A., Cole A. Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities. Prenat. Diagn. 20:2000;976-978.
23. Szabó J., Gellén J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet. I:1990;336.
24. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester. BMJ. 304:1992;867-869.
25. Sherer D.M., Manning F.A. First-trimester nuchal translucency screening for fetal aneuploidy. Am. J. Perinatol. 16:1999;103-120.
26. Pandya P.P., Snijders R.J., Johnson S.P., De Lourdes Brizot M., Nicolaides K.H. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br. J. Obstet. Gynaecol. 102:1995;957-962.
27. Wald N.J., Hackshaw A.K. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat. Diagn. 18:1998;511-523.
28. Nicolaides K.H., Snijders R.J., Cuckle H.S. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat. Diagn. 18:1998;519-523.
29. Hyett J., Moscoso G., Nicolaides K. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses. Am. J. Med. Genet. 69:1997;207-216.
30. Von Kaisenberg C.S., Brand-Saberi B., Jonat W., Nicolaides K. Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses. Prenat. Neonatal Med. 4:1999;431-440.
31. Cicero S., Curcio P., Papageorghiou A., Sonek J., Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet. 358:2001;1665-1667.
32. Spencer K., Ong C.Y.T., Liao A.W.J., Nicolaides K.H. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat. Diagn. 20:2000;491-494.
33. de Graaf I.M., Cuckle H.S., Pajkrt E., Leschot N.J., Bleker O.P., van Lith J.M. Co-variables in first trimester maternal serum screening. Prenat. Diagn. 20:2000;186-189.
34. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat. Diagn. 20:2000;91-95.
35. Spencer K., Nicolaides K.H. First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A. Prenat. Diagn. 20:2000;683-684.
36. Spencer K., Ong C.Y., Liao A.W., Nicolaides K.H. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat. Diagn. 20:2000;792-794.
37. Spencer K., Ong C.Y., Liao A.W., Papademetriou D., Nicolaides K.H. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 20:2000;673-675.
38. Ong C.Y., Liao A.W., Spencer K., Munim S., Nicolaides K.H. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG. 107:2000;1265-1270.
39. Liao A.W., Heath V., Kametas N., Spencer K., Nicolaides K.H. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum. Reprod. 16:2001;1501-1504.
40. Royal College of Obstetricians and Gynecologists. Recommendations Arising from the Study Group on Screening for Down Syndrome in the First Trimester. http://www.rcog.org.uk/study/downsyndrome.html.
41. Malone F.D., Berkowitz R.L., Canick J.A., D'Alton M.E. First-trimester screening for aneuploidy: research or standard of care? Am. J. Obstet. Gynecol. 182:2000;490-496.
42. Bray I., Wright D.E., Davies C., Hook E.B. Joint estimation of Down syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenat. Diagn. 8:1998;9-20.
43. Cuckle H. Down syndrome fetal loss rate in early pregnancy. Prenat. Diagn. 19:1999;1177-1179.
44. Snijders R.J., Noble P., Sebire N., Souka A., Nicolaides K.H. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet. 352:1998;343-346.
45. Haddow J.E. Antenatal screening for Down's syndrome: where are we and where next? Lancet. 352:1998;336-337.
46. Spencer K., Spencer C.E., Power M., Moakes A., Nicolaides K.H. One stop clinic for risk assessment for fetal anomalies: a report of the first year of prospective screening for chromosome anomalies in the first trimester. BJOG. 107:2000;1271-1275.
47. Krantz D.A., Hallahan T.W., Orlandi F., Buchanan P., Larsen J.W., Macri J.N. First trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet. Gynecol. 96:2000;207-213.
48. Hyett J.A., Sebire N.J., Snijders R.J., Nicolaides K.H. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet. Gynecol. 7:1996;101-103.
49. Hook E.B., Hamerton J.L. The frequency of chromosome abnormalities detected in consecutive newborn studies - differences between studies-results by sex and by severity of phenotypic involvement. Hook E.B., Porter I.H. Population cytogenetics: studies in humans. 1977;63-79 Academic Press, New York.
50. Biagiotti R., Cariati E., Brizzi L., Cappelli G., D'Agata A. Maternal serum screening for trisomy 18 in the first trimester of pregnancy. Prenat. Diagn. 18:1998;907-913.
51. Tul N., Spencer K., Noble P., Chan C., Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 19:1999;1035-1042.
52. Spencer K., Ong C., Skentou H., Liao A.W., Nicolaides K.H. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 20:2000;411-416.
53. Spencer K., Tul N., Nicolaides K.H. Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat. Diagn. 20:2000;390-394.
54. Spencer K., Liao A.W., Skentou H., Cicero S., Nicolaides K.H. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 20:2000;495-499.
55. Hyett J., Perdu M., Sharland G., Snijders R., Nicolaides K.H. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ. 318:1999;81-85.
56. Adekunle O., Gopee A., El-Sayed M., Thilaganathan B. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br. J. Radiol. 72:1999;457-460.
57. Michailidis G., Economides D.L. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet. Gynecol. 17:2001;102-105.
58. Pajkrt E., Mol B.W., Bleker O.P., Bilardo C.M. Pregnancy outcome and nuchal translucency measurements in fetuses with a normal karyotype. Prenat. Diagn. 19:1999;1104-1108.
59. Souka A.P., Krampl E., Bakalis S., Heath V., Nicolaides K.H. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet. Gynecol. 18:2001;9-17.
60. Pandya P.P., Snijders R.J., Psara N., Hilbert L., Nicolaides K.H. The prevalence of non-viable pregnancy at 10-13 weeks of gestation. Ultrasound Obstet. Gynecol. 7:1996;170-173.
61. Bilardo C.M., Müller M.O., Pajkrt E. Outcome of fetuses with increased nuchal translucency. Curr. Opin. Obstet. Gynecol. 13:2001;169-174.
62. Wald N.J., Watt H.C., Hackshaw A.K. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N. Engl. J. Med. 341:1999;461-467.
63. Hackshaw A.K., Wald N.J. Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome. Prenat. Diagn. 21:2001;737-740.
64. Hackshaw A.K., Wald N.J. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat. Diagn. 21:2001;741-746.
65. Copel J.A., Bahado-Singh R.O. Prenatal screening for Down's syndrome - a search for the family's values. N. Engl. J. Med. 341:1999;521-522.
66. Bilardo C.M. Increased nuchal translucency and normal karyotype: coping with uncertainty. Ultrasound Obstet. Gynecol. 17:2001;99-101.
67. Cuckle H. Integrating antenatal Down's syndrome screening. Curr. Opin. Obstet. Gynecol. 13:2001;175-181.
68. Cuckle H. Time for a total shift to first-trimester screening for Down's syndrome. Lancet. 358:2001;1658-1659.
69. Beazoglou T., Heffley D., Kyriopoulos J., Vintzileos A., Benn P.A. Economic evaluation of prenatal screening for Down syndrome in the USA. Prenat. Diagn. 18:1998;1241-1252.
70. National Center for Health Statistics, 1999 Natality Data Set: CD-ROM Series 21; no. 12; May 2001: Hyattsville, MD.
71. Wald N.J., Densem J.W., Smith D., Klee G.G. Four-marker serum screening for Down's syndrome. Prenat. Diagn. 14:1994;707-716.
72. Wald N.J., Densem J.W., George L., Muttukrishna S., Knight P.G. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat. Diagn. 16:1996;143-152. Erratum: Prenat. Diagn. 17:1997;285-290.
73. Wald N.J., Hackshaw A.K., George L.M. Assay precision of serum α fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J. Med. Screen. 7:2000;74-77.